DDInter1001 DDInter1676
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ixabepilone {u} (Compound) treats {v} (Disease) breast cancer
Ixabepilone {u} (Compound) binds {v} (Gene) TUBB3
Ixabepilone {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Ixabepilone {u} (Compound) causes {v} (Side Effect) Dehydration
Ixabepilone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capecitabine
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Ixabepilone (Compound) treats breast cancer (Disease)
Ixabepilone (Compound) binds TUBB3 (Gene)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Ixabepilone (Compound) causes Dehydration (Side Effect)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Clozapine
Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated